Cilostazol minimizes venous ischemic injury in diabetic and normal rats

We evaluated the effects of cilostazol on venous infarction produced by a photothrombotic two-vein occlusion (2VO) model in diabetic and control rats. The cerebral blood flow (CBF) between the occluded veins was measured by laser Doppler flowmetry for 4 hours after 2VO. Infarct size and immunohistochemistry were evaluated 24, 48, 96, and 168 hours after 2VO. Cilostazol was administered 1 hour after 2VO, and thereafter at a continuous oral dose of 60 mg/kg per day. Cilostazol reduced the infarct size, and the number of terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling (TUNEL)-positive apoptotic and B-cell lymphoma 2-associated X protein (Bax)-positive cells, and improved the CBF in control rats. In diabetic rats, cilostazol reduced the infarct size, and the number of TUNEL-positive apoptotic and Bax-positive cells, 96 and 168 hours after 2VO, but did not improve the CBF 4 hours after 2VO. Cilostazol increased the number of B-cell lymphoma 2 (Bcl-2)-positive cells in both strains 48, 96, and 168 hours after 2VO, but did not improve vessel wall thickness or collagen deposits. Cilostazol appeared to limit venous infarcts by improving the penumbral CBF in nondiabetic rats, and inhibited pro-apoptotic changes through Bcl-2 overexpression, without improving the CBF in diabetic rats.

[1]  T. Iwama,et al.  Combination Treatment with Normobaric Hyperoxia and Cilostazol Protects Mice against Focal Cerebral Ischemia-Induced Neuronal Damage Better Than Each Treatment Alone , 2009, Journal of Pharmacology and Experimental Therapeutics.

[2]  Masayoshi Takeuchi,et al.  Glycation—a sweet tempter for neuronal death , 2003, Brain Research Reviews.

[3]  Mitsutoshi Nakamura,et al.  Sequential and spatial profiles of apoptosis in ischemic penumbra after two-vein occlusion in rats. , 2006, Journal of neurosurgery.

[4]  Hideki Ito,et al.  Cilostazol, a Phosphodiesterase Inhibitor, Attenuates Photothrombotic Focal Ischemic Brain Injury in Hypertensive Rats , 2010, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[5]  H. Makino,et al.  Mechanisms involved in the stimulatory effect of advanced glycation end products on growth of rat aortic smooth muscle cells. , 2003, Metabolism: clinical and experimental.

[6]  K. Kawano,et al.  Spontaneous Long-Term Hyperglycemic Rat With Diabetic Complications: Otsuka Long-Evans Tokushima Fatty (OLETF) Strain , 1992, Diabetes.

[7]  F. Faraci,et al.  Impaired Endothelium-Dependent Responses and Enhanced Influence of Rho-Kinase in Cerebral Arterioles in Type II Diabetes , 2005, Stroke.

[8]  J. Hallenbeck,et al.  The Protective Effect of Ceramide in Immature Rat Brain Hypoxia—Ischemia Involves Up-Regulation of BCL-2 and Reduction of TUNEL-Positive Cells , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[9]  R. Duckrow,et al.  Regional cerebral blood flow decreases during chronic and acute hyperglycemia. , 1987, Stroke.

[10]  S. Black,et al.  A nitric oxide donor reduces brain injury and enhances recovery of cerebral blood flow after hypoxia-ischemia in the newborn rat , 2007, Neuroscience Letters.

[11]  I. Nakagawa,et al.  MitoKATP-Channel Opener Protects against Neuronal Death in Rat Venous Ischemia , 2005, Neurosurgery.

[12]  H. Nakase,et al.  Local Cerebral Blood Flow in a Rat Cortical Vein Occlusion Model , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[13]  H. Nakase,et al.  Vascular Endothelial Growth Factor Antagonist Reduces Brain Edema Formation and Venous Infarction , 2005, Stroke.

[14]  V. Salomaa,et al.  Diabetes and macrovascular disease. , 1996, Journal of cardiovascular risk.

[15]  Y. Ohashi,et al.  Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial , 2010, The Lancet Neurology.

[16]  H. Nakase,et al.  Effect of age on cerebral venous circulation disturbances in the rat. , 2000, Journal of neurosurgery.

[17]  Jiajun Zhao,et al.  Cilostazol Protects Diabetic Rats from Vascular Inflammation via Nuclear Factor-κB-Dependent Down-Regulation of Vascular Cell Adhesion Molecule-1 Expression , 2006, Journal of Pharmacology and Experimental Therapeutics.

[18]  J. Rafols,et al.  Cerebral ischemia-induced apoptosis and necrosis in normal and diabetic rats: Effects of insulin and C-peptide , 2006, Brain Research.

[19]  R. J. Dumont,et al.  Chronic Endothelin Antagonism Restores Cerebrovascular Function in Diabetes , 2003, Neurosurgery.

[20]  C. Kim,et al.  Protective Effects of Cilostazol against Transient Focal Cerebral ischemia and Chronic Cerebral Hypoperfusion Injury , 2008, CNS neuroscience & therapeutics.

[21]  H. Nakase,et al.  Modelling of the ischemic penumbra. , 1999, Acta neurochirurgica. Supplement.

[22]  J. Whisnant.  Modeling of risk factors for ischemic stroke. The Willis Lecture. , 1997, Stroke.

[23]  Yasushi Motoyama,et al.  Enhanced cerebral ischemic lesions after two-vein occlusion in diabetic rats , 2010, Brain Research.